<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366949">
  <stage>Registered</stage>
  <submitdate>22/08/2014</submitdate>
  <approvaldate>15/10/2014</approvaldate>
  <actrnumber>ACTRN12614001095651</actrnumber>
  <trial_identification>
    <studytitle>Beta-blockers in COPD (Chronic Obstructive Pulmonary Disease): Feasibility of a Randomised Controlled Trial</studytitle>
    <scientifictitle>Beta-blockers in COPD: Feasibility of a Randomised Controlled Trial</scientifictitle>
    <utrn>U1111-1157-1547</utrn>
    <trialacronym />
    <secondaryid>None
</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Obstructive Pulmonary Disease (COPD)
</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Chronic obstructive pulmonary disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Feasibility of starting a cardioselective beta-blocker (metoprolol) in patients with an exacerbation of COPD. Participants will be given a test dose of 12.5 mg standard oral metoprolol in hospital. If this is tolerated, they will be commenced on a low dose of 23.75mg controlled-release metoprolol on daily. The dose will be increased after two weeks to 47.5mg daily and after a further 4 weeks to 95mg daily if tolerated. The duration of treatment will be 3 months. </interventions>
    <comparator>not applicable</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Whether participants tolerate beta-blocker treatment according to patients and clinician judgement. Patients may be able to tolerate a lower dose of beta-blocker, but not the target dose of 95mg. The primary outcome is whether beta-blocker therapy is stopped completely.</outcome>
      <timepoint>3 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse effects. These include acute bronchospasm, postural dizziness, falls, severe bradycardia, heart block. Symptoms will be recorded, ECG, spirometry, blood pressure and pulse will be measured at each clinic assessment prior to each dose increase.</outcome>
      <timepoint>3 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Admitted to hospital with an exacerbation of COPD
Spirometry confirms COPD
At least 10 pack year smoking history</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Acute coronary syndrome
Already treated with beta-blocker
Major contra-indication to cardio-selective beta-blocker
Terminal illness
Primary admission diagnosis of pneumonia or other acute respiratory disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Eligible participants who consent to take part will be enrolled. All participants will receive active treatment: this is a feasibility study to determine if a larger randomised-controlled trial can be done.</concealment>
    <sequence>not applicable</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods>Descriptive only</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>17/10/2014</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>48</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Robert Hancox</primarysponsorname>
    <primarysponsoraddress>Department of Preventive and Social Medicine,
Dunedin School of Medicine, 
University of Otago,
PO Box 56,
Dunedin
9054

</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health Research Council (NZ)</fundingname>
      <fundingaddress>Level 3,
110 Stanley Street,
Auckland 1010.

PO Box 5541, 
Wellesley Street, 
Auckland 1141.</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Otago</sponsorname>
      <sponsoraddress>PO Box 56,
Dunedin,
9054</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Catherina Chang</othercollaboratorname>
      <othercollaboratoraddress>Department of Respiratory Medicine,
Waikato Hospital,
Pembroke Street,
Hamilton 3240
</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Associate Professor Lutz Beckert</othercollaboratorname>
      <othercollaboratoraddress>Department of Medicine
University of Otago
2 Riccarton Avenue, 
PO Box 4345, 
Christchurch 8140</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Professor Richard Beasley</othercollaboratorname>
      <othercollaboratoraddress>Medical Research Institute of New Zealand/Capital Coast DHB,
Private Bag 7902, Newtown 
Wellington 6242
</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Kyle Perrin</othercollaboratorname>
      <othercollaboratoraddress>Department of Medicine
University of Otago
23A Mein St, Newtown.
Wellington 6021
</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Conroy Wong</othercollaboratorname>
      <othercollaboratoraddress>Department of Respiratory Medicine
Middlemore Hospital
Otahuhu
Private Bag 93311
Auckland 2025</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Associate Professor Robert Young</othercollaboratorname>
      <othercollaboratoraddress>Department of Medicine
University of Auckland/Auckland DHB
Auckland City Hospital
Private Bag 92019
Auckland 1142</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Beta-blocker treatment is known to improve survival from several cardiac diseases. Unfortunately, beta-blockers are usually avoided in patients with chronic obstructive pulmonary disease (COPD) because of concerns that they may make airflow obstruction worse. Therefore patients with COPD are often deprived of the benefits of beta-blockers even though they have a very high risk of cardiac problems. Recent evidence suggests that beta-blockers may be safe and effective in lung disease but there have been no clinical studies to confirm this. This feasibility study will assess the safety and tolerability of metoprolol, a cardio-selective beta-blocker, in patients with exacerbations of COPD to determine whether a randomised controlled trial of beta-blockers should be conducted. The randomised study would provide a definitive answer on whether beta-blockers are safe and effective in patients with chronic obstructive pulmonary disease. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern B Health and Disability Ethics Committee</ethicname>
      <ethicaddress>Health and Disability Ethics Committees
Ministry of Health 
C/- MEDSAFE, Level 6, Deloitte House 
10 Brandon Street 
PO Box 5013 
Wellington 6011</ethicaddress>
      <ethicapprovaldate>9/07/2014</ethicapprovaldate>
      <hrec>14/NTB/88</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Robert Hancox</name>
      <address>Department of Preventive and Social Medicine,
Dunedin School of Medicine, 
P.O. Box 913
University of Otago,
Dunedin.
9054
</address>
      <phone>+64 3 4798512</phone>
      <fax />
      <email>bob.hancox@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Robert Hancox</name>
      <address>Department of Preventive and Social Medicine,
Dunedin School of Medicine, 
P.O. Box 913
University of Otago,
Dunedin.
9054</address>
      <phone>+64 3 4798512</phone>
      <fax />
      <email>bob.hancox@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Robert Hancox</name>
      <address>Department of Preventive and Social Medicine,
Dunedin School of Medicine, 
P.O. Box 913
University of Otago,
Dunedin.
9054</address>
      <phone>+64 3 4798512</phone>
      <fax />
      <email>bob.hancox@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>